# AARD (Aardvark Therapeutics, Inc.) - SEC EDGAR Financial Statements

> Aardvark Therapeutics, Inc. reported $0 in revenue and a net loss of $72.76M for the trailing twelve months ended September 30, 2026.

- Canonical: https://convexityos.com/fundamentals/AARD
- Markdown: https://convexityos.com/fundamentals/AARD.md
- SEC CIK: 0001774857
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 21, 2026, 05:02 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001774857&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | TTM | $0 | Sep 30, 2026 |
| Operating Income | TTM | -$75.97M | Operating profit |
| Net Income | TTM | -$72.76M | GAAP bottom line |
| Diluted EPS | TTM | -$3.32 | Split-adjusted |
| Free Cash Flow | TTM | -$54.27M | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $60.35M | Total debt: $572K |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 |
| --- | --- | --- |
| **Revenue** | $0 | -- |
| Research & Development | $48.94M | $17.36M |
| Total Operating Expenses | $62.73M | $22.79M |
| **Operating Income** | -$62.73M | -$22.79M |
| **EBITDA** | -$62.69M | -$22.77M |
| Interest Income | $5.14M | $2.41M |
| Income Tax Expense | $0 | $0 |
| **Net Income** | -$57.59M | -$20.59M |
| Basic EPS | -$24.83 | -$43.64 |
| **Diluted EPS** | -$24.83 | -$43.64 |
| Basic Shares Outstanding | 2.3M | 471.6K |
| Diluted Shares Outstanding | 2.3M | 471.6K |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -- |
| Research & Development | $15.67M | $10.46M | $16.57M | $14.30M | $13.74M | $13.14M | $7.75M | $8.06M |
| Total Operating Expenses | $19.72M | $15.08M | $22.46M | $18.70M | $17.70M | $15.85M | $10.47M | $9.45M |
| **Operating Income** | -$19.72M | -$15.08M | -$22.46M | -$18.70M | -$17.70M | -$15.85M | -$10.47M | -$9.45M |
| **EBITDA** | -$19.71M | -$15.07M | -$22.45M | -$18.69M | -$17.69M | -$15.84M | -$10.46M | -$9.44M |
| Interest Income | $539K | $695K | $889K | $1.12M | $1.35M | $1.49M | $1.18M | $717K |
| **Net Income** | -$19.19M | -$14.39M | -$21.59M | -$17.60M | -$16.32M | -$14.37M | -$9.31M | -$8.78M |
| Basic EPS | -$0.88 | -$0.66 | -$8.39 | -- | -$0.75 | -$0.66 | -$6.02 | -- |
| **Diluted EPS** | -$0.88 | -$0.66 | -$8.39 | -- | -$0.75 | -$0.66 | -$6.02 | -- |
| Basic Shares Outstanding | 21.9M | 21.8M | 2.6M | -- | 21.7M | 21.7M | 1.6M | -- |
| Diluted Shares Outstanding | 21.9M | 21.8M | 2.6M | -- | 21.7M | 21.7M | 1.6M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 |
| --- | --- | --- |
| Cash & Cash Equivalents | $47.05M | $61.64M |
| Short-Term Investments | $62.98M | $12.02M |
| **Cash & Short-Term Investments** | $110.0M | $73.66M |
| **Total Current Assets** | $111.9M | $74.14M |
| Other Non-Current Assets | $4.94M | $2.63M |
| **Total Non-Current Assets** | $5.29M | $3.37M |
| **Total Assets** | $117.2M | $77.51M |
| Accounts Payable | $2.07M | $2.30M |
| **Total Current Liabilities** | $10.55M | $4.93M |
| Other Non-Current Liabilities | $0 | $26K |
| **Total Non-Current Liabilities** | $0 | $467K |
| **Total Liabilities** | $10.55M | $5.39M |
| **Total Debt (incl. Leases)** | $441K | $779K |
| Common Stock | $0 | $0 |
| Retained Earnings | -$115.9M | -$58.33M |
| Accumulated Other Comp. Income | $81K | $0 |
| **Total Stockholders' Equity** | $106.6M | -$54.64M |
| Total Equity | $106.6M | -$54.64M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $60.34M | $73.85M | $62.44M | $47.05M | $39.28M | $26.00M | $26.50M | $61.64M |
| Short-Term Investments | $13K | $21K | $28.76M | $62.98M | $87.06M | $115.8M | $124.8M | $12.02M |
| **Cash & Short-Term Investments** | $60.30M | $73.90M | $91.20M | $110.0M | $126.4M | $141.8M | $151.3M | $73.66M |
| **Total Current Assets** | $64.11M | $80.66M | $93.58M | $111.9M | $129.2M | $144.8M | $154.6M | $74.14M |
| Other Non-Current Assets | $162K | $173K | $4.74M | $4.94M | $3.58M | $2.19M | $1.84M | $2.63M |
| **Total Non-Current Assets** | $694K | $799K | $5.01M | $5.29M | $4.02M | $2.71M | $2.47M | $3.37M |
| **Total Assets** | $64.80M | $81.46M | $98.59M | $117.2M | $133.2M | $147.5M | $157.0M | $77.51M |
| Accounts Payable | $1.59M | $2.09M | $4.49M | $2.07M | $4.44M | $5.06M | $2.56M | $2.30M |
| **Total Current Liabilities** | $7.03M | $6.39M | $11.60M | $10.55M | $10.74M | $10.31M | $5.98M | $4.93M |
| Other Non-Current Liabilities | -- | -- | -- | $0 | $0 | $12K | $24K | $26K |
| **Total Non-Current Liabilities** | $159K | $276K | $0 | $0 | $116K | $240K | $360K | $467K |
| **Total Liabilities** | $7.19M | $6.66M | $11.60M | $10.55M | $10.85M | $10.55M | $6.34M | $5.39M |
| **Total Debt (incl. Leases)** | $572K | $677K | $336K | $441K | $545K | $645K | $726K | $779K |
| Common Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Retained Earnings | -$171.1M | -$151.9M | -$137.5M | -$115.9M | -$98.32M | -$82.00M | -$67.64M | -$58.33M |
| Accumulated Other Comp. Income | $0 | $0 | $14K | $81K | $82K | -$3.0K | $44K | $0 |
| **Total Stockholders' Equity** | $57.61M | $74.80M | $86.99M | $106.6M | $122.4M | $136.9M | $150.7M | -$54.64M |
| Total Equity | $57.61M | $74.80M | $86.99M | $106.6M | $122.4M | $136.9M | $150.7M | -$54.64M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 |
| --- | --- | --- |
| Net Income | -$57.59M | -$20.59M |
| Depreciation & Amortization | $36K | $16K |
| Stock-Based Compensation | $3.95M | $439K |
| Change in Payables | $239K | $798K |
| **Operating Cash Flow** | -$54.17M | -$18.09M |
| Capital Expenditure | -$95K | -$109K |
| **Free Cash Flow** | -$54.27M | -$18.20M |
| **Investing Cash Flow** | -$49.67M | -$12.00M |
| Common Stock Issued | $195K | $0 |
| **Financing Cash Flow** | $89.25M | $81.99M |
| **Net Change in Cash** | -$14.59M | $51.91M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$19.19M | -$14.39M | -$21.59M | -$17.60M | -$16.32M | -$14.37M | -$9.31M | -$8.78M |
| Depreciation & Amortization | $10K | $11K | $11K | $10K | $10K | $11K | $5.0K | $8.0K |
| Stock-Based Compensation | $1.97M | $1.95M | $2.00M | $1.58M | $1.50M | $634K | $233K | $173K |
| Change in Payables | -$497K | -$2.41M | $2.42M | -$2.37M | -$612K | $2.58M | $648K | $1.19M |
| **Operating Cash Flow** | -$13.54M | -$17.60M | -$18.87M | -$16.81M | -$16.13M | -$9.84M | -$11.39M | -$7.73M |
| Capital Expenditure | -- | -- | -- | $0 | -$4.0K | -$91K | $0 | -$6.0K |
| **Free Cash Flow** | -- | -- | -- | -$16.81M | -$16.13M | -$9.94M | -$11.39M | -$7.73M |
| **Investing Cash Flow** | $0 | $28.75M | $34.25M | $24.30M | $29.25M | $9.41M | -$112.6M | -$11.89M |
| **Financing Cash Flow** | $22K | $262K | $4.0K | $274K | $171K | -$71K | $88.88M | -$1.01M |
| **Net Change in Cash** | -$13.51M | $11.41M | $15.38M | $7.77M | $13.29M | -$506K | -$35.14M | -$20.64M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 |
| --- | --- | --- |
| Return on Equity (ROE) | -54.0% | -- |
| Return on Assets (ROA) | -49.1% | -26.6% |
| Current Ratio | 10.61x | 15.05x |
| Quick Ratio | 10.43x | 14.95x |
| Debt to Equity | 0.00x | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -126.3% | -93.4% | -80.3% | -54.0% | -39.9% | -26.8% | -18.4% | -- |
| Return on Assets (ROA) | -112.3% | -85.8% | -70.9% | -49.1% | -36.6% | -24.8% | -17.7% | -26.6% |
| Current Ratio | 9.11x | 12.63x | 8.06x | 10.61x | 12.03x | 14.04x | 25.86x | 15.05x |
| Quick Ratio | 8.57x | 11.57x | 7.86x | 10.43x | 11.77x | 13.75x | 25.32x | 14.95x |
| Debt to Equity | 0.01x | 0.01x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
